FCRL5

FCRL5 Overview

English NameFc receptor-like protein 5Approved Drugs0
Drugs in Clinical Trials3Target SynonymFc Receptor-Like 5,CD307e Antigen,PRO820,CD307e,Fc Receptor Like 5,FcR-like protein 5,BXMAS1,Fc receptor homolog 5,FcRH5,Immune receptor translocation-associated protein 2,CD_antigen: CD307e,IRTA2,Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2)
Highest Development StagePhase 2 Clinical
English NameFc receptor-like protein 5
Target SynonymFc Receptor-Like 5,CD307e Antigen,PRO820,CD307e,Fc Receptor Like 5,FcR-like protein 5,BXMAS1,Fc receptor homolog 5,FcRH5,Immune receptor translocation-associated protein 2,CD_antigen: CD307e,IRTA2,Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2)
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 2 Clinical

FCRL5 Background

May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells.

FCRL5 Synonyms

BXMAS1, CD307, CD307e, FCRH5, IRTA2, PRO820

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
Anti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
CevostamabRG-6160; BFCR-4350A; RO-7187797Phase 2 ClinicalGenentech IncLupus Erythematosus, Systemic; Multiple Myeloma
Details
  • Overview
  • Product List
  • Clinical Drug Information